CareDx, Inc
CareDx, Inc (CDNA) Financial Performance & Income Statement Overview
Access detailed quarterly and annual financial reports for CareDx, Inc (CDNA), covering cash flow, earnings, and balance sheets.
CareDx, Inc (CDNA) Income Statement & Financial Overview
Analyze CareDx, Inc’s CDNA earnings with segmented quarterly and yearly financial statement figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $84.69M | $86.58M | $82.88M | $92.27M |
| Cost of Revenue | $28.41M | $28.18M | $27.57M | $28.57M |
| Gross Profit | $56.27M | $58.40M | $55.31M | $63.70M |
| Gross Profit Ratio | $0.66 | $0.67 | $0.67 | $0.69 |
| R&D Expenses | $18.52M | $16.53M | $17.49M | $19.68M |
| SG&A Expenses | $45.76M | $61.76M | $48.32M | $48.68M |
| Operating Expenses | $69.64M | -$16.29M | $65.80M | $67.73M |
| Total Costs & Expenses | $98.06M | $11.89M | $93.38M | $96.30M |
| Interest Income | $0.00 | $3.05M | $3.001M | $2.83M |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $0.00 | $4.69M | $4.89M | $4.96M |
| EBITDA | -$13.37M | $84.38M | -$5.60M | $927000.00 |
| EBITDA Ratio | -$0.16 | $0.97 | -$0.07 | $0.01 |
| Operating Income | -$13.37M | $74.69M | -$10.49M | -$4.03M |
| Operating Income Ratio | -$0.16 | $0.86 | -$0.13 | -$0.04 |
| Other Income/Expenses (Net) | $3.08M | $3.49M | $3.28M | $2.73M |
| Income Before Tax | -$10.29M | $78.18M | -$7.21M | -$1.37M |
| Income Before Tax Ratio | -$0.12 | $0.90 | -$0.09 | -$0.01 |
| Income Tax Expense | $58000.00 | -$171000.00 | $200000.00 | $22000.00 |
| Net Income | -$10.35M | $78.01M | -$7.41M | -$1.39M |
| Net Income Ratio | -$0.12 | $0.90 | -$0.09 | -$0.02 |
| EPS | -$0.19 | $1.62 | -$0.14 | -$0.03 |
| Diluted EPS | -$0.19 | $1.51 | -$0.14 | -$0.03 |
| Weighted Avg Shares Outstanding | $55.26M | $52.77M | $52.90M | $52.20M |
| Weighted Avg Shares Outstanding (Diluted) | $55.26M | $56.62M | $52.90M | $52.20M |
Over the past four quarters, CareDx, Inc demonstrated steady revenue growth, increasing from $92.27M in Q2 2024 to $84.69M in Q1 2025. Operating income reached -$13.37M in Q1 2025, maintaining a consistent -16% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at -$13.37M, reflecting operational efficiency. Net income dropped to -$10.35M, with EPS at -$0.19. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan